Found 1864 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
Hematological Malignancies
People with hematological malignancies are asked to participate in a research study being conducted by Albert Einstein College of Medicine.
- 9 views
- 09 Jan, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
Hematological Malignancies
People with hematological cancers are asked to participate in a research study being conducted by CLL Research and Treatment Program/Northwell Health Cancer Institute//Feinstein Institute for Medical Research and Zucker School of Medicine at Hofstra-Northwell
- 28 views
- 27 Jun, 2019
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Hematology
-
Currently Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases
- 86 views
- 22 Dec, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting Seniors
-
Hematology
-
Currently Recruiting
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the
- 123 views
- 22 Dec, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
Advanced Stage Non-small Cell Lung Cancer
Advanced Stage Non-small Cell Lung Cancer
- 200 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
Currently Recruiting
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
- 290 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
Do you suffer from Hemorrhoids?
Do you suffer from Hemorrhoids?
- 1312 views
- 08 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Intra Bone Marrow Injection Of Unrelated Cord Blood Cells
Compared to other stemcell sources cord blood (CB) is easier and safer to procure, has no donor attrition, a limitless supply, reduced viral transmission, less acute & chronic GVHD, is rich in hematopoietic progenitor cells, and immaturity of T-cell-mediated immunity. CB has delayed neutrophil and platelet engraftment, a prolonged immune …
- 15 views
- 07 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation
In stem cell transplantation as treatment for malignant diseases, calcineurin inhibitors like cyclosporine A are commonly used to prevent tissue destruction (GvHD) by activated donor immune cells. The hypothesis for this study is, that replacing calcineurin inhibitors by everolimus and mycophenolate as GvHD prophylaxis not only reduces toxicity of the …
- 9 views
- 07 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in lymphoid hematological refractory or multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available. …
- 6 views
- 24 Jan, 2021
- 2 locations